Millendo Therapeutics Inc (NASDAQ:MLND) – Analysts at Wedbush issued their Q2 2019 earnings per share estimates for Millendo Therapeutics in a research note issued on Thursday, July 18th, Zacks Investment Research reports. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.81) per share for the quarter. Wedbush has a “Outperform” rating and a $24.00 price objective on the stock. Wedbush also issued estimates for Millendo Therapeutics’ Q1 2020 earnings at ($0.86) EPS, Q2 2020 earnings at ($0.88) EPS, Q3 2020 earnings at ($0.89) EPS, Q4 2020 earnings at ($0.89) EPS and FY2020 earnings at ($3.51) EPS.
Other analysts have also issued reports about the company. Oppenheimer began coverage on Millendo Therapeutics in a report on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 price target on the stock. CIBC started coverage on Millendo Therapeutics in a report on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 price target on the stock. Citigroup started coverage on Millendo Therapeutics in a report on Monday, July 15th. They set an “outperform” rating and a $26.00 target price on the stock. ValuEngine upgraded Millendo Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Zacks Investment Research upgraded Millendo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $24.38.
Shares of Millendo Therapeutics stock traded down $0.74 during trading on Monday, reaching $7.82. The stock had a trading volume of 18,400 shares, compared to its average volume of 38,358. The company has a market cap of $114.58 million, a P/E ratio of -0.44 and a beta of 2.64. The business’s fifty day simple moving average is $11.18. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02.
Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08).
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio bought a new stake in Millendo Therapeutics during the second quarter worth about $28,000. Geode Capital Management LLC bought a new stake in Millendo Therapeutics during the fourth quarter worth about $113,000. Private Advisors LLC raised its holdings in Millendo Therapeutics by 9.1% during the first quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after acquiring an additional 1,279 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in Millendo Therapeutics during the first quarter worth about $303,000. Finally, BlackRock Inc. bought a new stake in Millendo Therapeutics during the fourth quarter worth about $203,000. Institutional investors and hedge funds own 44.08% of the company’s stock.
About Millendo Therapeutics
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company’s lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing’s syndrome.